RCP
APGE icon

Remedium Capital Partners’s Apogee Therapeutics APGE Stock Holding History

Remedium Capital Partners’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.9M Buy
586,691
+3,100
+0.5% +$279K 17.24% 3
2026
Q1 		$49.1M Hold
583,591
– – 17.47% 4
2025
Q4 		$44M Buy
+583,591
New +$36.8M 25.88% 3

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Remedium Capital Partners's APGE Position: Q2 2026 in Review

Remedium Capital Partners increased its Apogee Therapeutics (APGE) stake by 0.53% in Q2 2026, buying an estimated $279K and bringing the position to 586,691 shares worth $77.9M. The position accounts for 17.24% of the portfolio, ranked #3.

Remedium Capital Partners first reported a position in APGE in Q4 2025 and has held it in 3 quarters since. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Remedium Capital Partners held 586,691 shares of Apogee Therapeutics worth $77.9M as of Q2 2026.
  • Remedium Capital Partners bought 3,100 Apogee Therapeutics shares in Q2 2026, an estimated $279K.
  • Apogee Therapeutics made up 17.24% of Remedium Capital Partners's portfolio in Q2 2026, its #3 holding.
  • Remedium Capital Partners first reported a position in Apogee Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Remedium Capital Partners's 13F filing for Q2 2026, filed 7 Aug 2026.